Tasurgratinib Tablets 35 mg Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 35 mg
Reference Brands: Tasfygo (Japan)
Category: Oncology Cancer Care
Tasurgratinib (Tasfygo, Eisai) is an oral FGFR inhibitor for biliary tract cancer with an FGFR2 gene fusion after chemotherapy. It was approved in Japan in September 2024 and is not approved in the US or EU. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.
Manufacture or export Tasurgratinib Tablets? List it or send an offer →
Product Description:
Tasurgratinib is a tyrosine kinase inhibitor of the fibroblast growth factor receptors FGFR1, 2 and 3. About one in ten to one in seven intrahepatic cholangiocarcinomas are driven by an FGFR2 gene fusion, which keeps the receptor switched on. Blocking it slows or shrinks these tumours.
Japan approved tasurgratinib as Tasfygo in September 2024 for unresectable biliary tract cancer with an FGFR2 fusion that has progressed after chemotherapy. It is taken by mouth as 35 mg tablets. A raised blood phosphate level is a typical class side effect and is monitored. Tasurgratinib is approved only in Japan.
Sourcing and licensing notes. Tasurgratinib is patented and made only by Eisai; there is no generic. Other FGFR inhibitors for this cancer on PharmaTradz include pemigatinib and futibatinib. Because it is a Japan-only product, supply elsewhere goes through named-patient or import-permit routes, which we confirm for each destination.
How Tasurgratinib Tablets is supplied today, and licensing ahead of patent expiry
Where tasurgratinib is approved
Checked 3 Oct 2026| Market | Status | Brand · regulator · date |
|---|---|---|
| Japan | Approved | Tasfygo · MHLW · Sep 2024 |
| United States | Not approved | Not approved as of the check date |
| European Union | Not approved | Not approved as of the check date |
| Generic / biosimilar | None | None approved as of the check date |
Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →
Frequently Asked Questions
Biliary tract cancer with an FGFR2 gene fusion that has progressed after chemotherapy.
Tasfygo, from Eisai. It was approved in Japan in September 2024.
No. It is approved only in Japan; elsewhere it can only be supplied through named-patient or import-permit routes.
No. It is patented. We handle authorised-supply enquiries and connect developers and licensees preparing for patent expiry.
Related Products
Gedatolisib for Injection
Strength:
180 mg
Form: Powder vial (IV infusion)
Reference Brands: Revtorpyk
View DetailsSerplulimab Injection
Strength:
100 mg/10 mL
Form: Concentrate vial (IV infusion)
Reference Brands: Hetronifly (EU), Hansizhuang (China)
View DetailsPivekimab Sunirine for Injection
Strength:
2 mg
Form: Lyophilised powder vial (IV infusion)
Reference Brands: Decnupaz
View DetailsZanidatamab for Injection
Strength:
300 mg
Form: Lyophilised powder vial (IV infusion)
Reference Brands: Ziihera
View Details
Usually answered within 48 hours | GMP documents shared before you commit
